Last reviewed · How we verify
Janssen Sciences Ireland UC — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
10 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| FTC/TDF FDC | FTC/TDF FDC | phase 3 | Nucleoside/nucleotide reverse transcriptase inhibitor combination | HIV reverse transcriptase | Infectious Disease |
Therapeutic area mix
- Infectious Disease · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 1 shared drug class
- Brigham and Women's Hospital · 1 shared drug class
- Fundacion IDEAA · 1 shared drug class
- Merck Sharp & Dohme LLC · 1 shared drug class
- National Institute of Allergy and Infectious Diseases (NIAID) · 1 shared drug class
- University of Chicago · 1 shared drug class
- University of Washington · 1 shared drug class
- ViiV Healthcare · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Janssen Sciences Ireland UC:
- Janssen Sciences Ireland UC pipeline updates — RSS
- Janssen Sciences Ireland UC pipeline updates — Atom
- Janssen Sciences Ireland UC pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Janssen Sciences Ireland UC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/janssen-sciences-ireland-uc. Accessed 2026-06-10.